


Express Mail Label No. EK611913420US

Date of Deposit: December 19, 2000

Attorney Docket No. 15966-577 (CURA-77)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 22 2000

TECH CENTER 1600/2900

APPLICANTS: Shimkets, *et al.*
ASSIGNEE: CuraGen Corporation
SERIAL NUMBER: 09/662,783 EXAMINER: Not Yet Assigned
FILING DATE: September 12, 2000 ART UNIT: 1646
FOR: GROWTH FACTOR POLYPEPTIDES AND NUCLEIC ACIDS ENCODING
SAME

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (5 pages);
- ☒ Modified Form 1449/PTO (4 pages) in duplicate;
- ☒ Copies of Cited references A1-A8, B1-B6 and C1-C66;
- ☒ Return Postcard

No fee is believed to be due at this time. However, the Commissioner is hereby authorized to charge any additional fees that may be due to Deposit Account No. 50-0311, Reference No. 15966-57 (CURA-77). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Kristin E. Konzak, Reg. No. 44,848


c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

DATE: December 19, 2000

Express Mail Label No. K611913420US

Date of Deposit: December 19, 2000

Attorney Docket No. CURA-77 (15966-577)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3
1.02
12/28/00
RECEIVED

DEC 22 2000

TECH CENTER 1600/2900

APPLICANTS: Shimkets *et al.*
ASSIGNEE: CuraGen Corporation
SERIAL NUMBER: 09/662,783 EXAMINER: Not Yet Assigned
FILING DATE: September 12, 2000 ART UNIT: 1646
FOR: GROWTH FACTOR POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

December 19, 2000
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent Documents:

A1	4,816,567	3/28/89	Cabilly, et al.
A2	5,225,539	7/6/93	Winter
A3	5,545,807	8/13/96	Surani, et al.
A4	5,545,806	8/13/96	Lonberg, et al.
A5	5,569,825	10/29/96	Lonberg, et al.
A6	5,625,126	4/29/97	Lonberg, et al.
A7	5,939,598	8/17/99	Kucherlapati, et al.
A8	5,916,771	6/29/99	Hori, et al.

Foreign Patent Documents:

B1	WO	96/41892	Mileham, et al.	12/27/96
B2	WO	00/27879	Eriksson, et al.	5/18/00
B3	WO	94/02602	Kucherlapati, et al.	2/3/94
B4	WO	96/33735	Kucherlapati, et al.	10/31/96
B5	WO	96/34096	Kucherlapati, et al.	10/31/96
B6	WO	99/53049	Davis, et al.	10/21/99

Other Prior Art – Non Patent Literature Documents:

- C1 Alon, T., I. Hemo, et al. (1995). "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity." Nat Med 1(10): 1024-8.
- C2 Athanassiades, A. and P. K. Lala (1998). "Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness." Placenta 19(7): 465-73.
- C3 Bellamy, W. T., L. Richter, et al. (1999). "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies." Cancer Res 59(3): 728-33.
- C4 Betsholtz, C., A. Johnsson, et al. (1986). "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines." Nature 320(6064): 695-9.
- C5 Bonthron, D. T., C. C. Morton, et al. (1988). "Platelet-derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing." Proc Natl Acad Sci U S A 85(5): 1492-6.
- C6 Carmeliet, P., M. G. Lampugnani, et al. (1999). "Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis." Cell 98(2): 147-57.
- C7 Collins, T., D. Ginsburg, et al. (1985). "Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis." Nature 316(6030): 748-50.
- C8 Cote, R. M., DM; Houghton, AN; Beattie, EJ; Oettgen, HF; Old, LJ (1983). "Generation of human monoclonal antibodies reactive with cellular antigens." Proc. Natl. Acad. Sci. USA 80: 2026-2030.
- C9 Dalla-Favera, R., E. P. Gelmann, et al. (1981). "A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus." Nature 292(5818): 31-5.
- C10 Doolittle, R. F., M. W. Hunkapiller, et al. (1983). "Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor." Science 221(4607): 275-7.
- C11 Ferrara, N. (1999). "Vascular endothelial growth factor: molecular and biological aspects." Curr Top Microbiol Immunol 237: 1-30.
- C12 Fishwild, D. M., S. L. O'Donnell, et al. (1996). "High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice [see comments]." Nat Biotechnol 14(7): 845-51.
- C13 Folkman, J. (1995). "Angiogenesis in cancer, vascular, rheumatoid and other disease." Nat Med 1(1): 27-31.
- C14 Gerber, H. P., A. McMurtrey, et al. (1998). "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation." J Biol Chem 273(46): 30336-43.
- C15 Gerber, H. P., V. Dixit, et al. (1998). "Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells." J Biol Chem 273(21): 13313-6.
- C16 Hamada, et al., 2000 "A novel gene derived from developing spinal cords, SCDGF, is a unique member of the PDGF/BEFF family." FEBS Lett. 475(2): 970-102. GenBank Accession Number: **BAB03265**
- C17 Helmlinger, G., M. Endo, et al. (2000). "Formation of endothelial cell networks." Nature 405(6783): 139-41.
- C18 Hermansson, M., M. Nister, et al. (1988). "Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation." Proc Natl Acad Sci U S A 85(20): 7748-52.
- C19 Holash, J., P. C. Maisonpierre, et al. (1999). "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF." Science 284(5422): 1994-8.
- C20 Hoogenboom, H. R. and G. Winter (1992). "By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro." J Mol Biol 227(2): 381-8.
- C21 Hopp, T. P. and K. R. Woods (1981). "Prediction of protein antigenic determinants from amino acid sequences." Proc Natl Acad Sci U S A 78(6): 3824-8.
- C22 Jones, P. T., P. H. Dear, et al. (1986). "Replacing the complementarity-determining regions in a human antibody with those from a mouse." Nature 321(6069): 522-5.
- C23 Josephs, S. F., C. Guo, et al. (1984). "Human-proto-oncogene nucleotide sequences corresponding to the transforming region of simian sarcoma virus." Science 223(4635): 487-91.
- C24 Katoh, M. and M. Terada (1996). "Overexpression of bone morphogenic protein (BMP)-4 mRNA in gastric cancer cell lines of poorly differentiated type." J Gastroenterol 31(1): 137-9.
- C25 Kelly, J. D., E. W. Raines, et al. (1985). "The B chain of PDGF alone is sufficient for mitogenesis." Embo J 4(13A): 3399-405.
- C26 Kessler, E., K. Takahara, et al. (1996). "Bone morphogenetic protein-1: the type I procollagen C-proteinase

- [see comments]." *Science* 271(5247): 360-2.
- C27 Kohler, G. and C. Milstein (1975). "Continuous cultures of fused cells secreting antibody of predefined specificity." *Nature* 256(5517): 495-7.
- C28 Kozbor, D. and J. Roder (1983). "The production of monoclonal antibodies from human lymphocytes." *Immunology Today* 4(3): 72-79.
- C29 Kozbor, D., P. Tripputi, et al. (1984). "A human hybrid myeloma for production of human monoclonal antibodies." *J Immunol* 133(6): 3001-5.
- C30 Kyte, J. and R. F. Doolittle (1982). "A simple method for displaying the hydropathic character of a protein." *J Mol Biol* 157(1): 105-32.
- C31 Li, et al., 2000 "PDGF-C is a novel protease-activated ligand for the PDGF alpha receptor." Nat. Cell Biol. Direct Submission. GenBank Accession Number: **AAF80597**
- C32 Li, J. M., J. S. Han, et al. (1999). "A novel gene delivery system targeting cells expressing VEGF receptors." *Cell Res* 9(1): 11-25.
- C33 Lonberg, N. and D. Huszar (1995). "Human antibodies from transgenic mice." *Int Rev Immunol* 13(1): 65-93.
- C34 Lonberg, N., L. D. Taylor, et al. (1994). "Antigen-specific human antibodies from mice comprising four distinct genetic modifications [see comments]." *Nature* 368(6474): 856-9.
- C35 Maeno, et al., 1993 "Cloning and expression of cDNA encoding *Zenopus laevis* bone morphogenetic protein-1 during early embryonic development." *Gene* 134(2): 257-261. GenBank Accession Number: **P98070**
- C36 Marks, J. D., A. D. Griffiths, et al. (1992). "By-passing immunization: building high affinity human antibodies by chain shuffling." *Biotechnology (N Y)* 10(7): 779-83.
- C37 Marks, J. D., H. R. Hoogenboom, et al. (1991). "By-passing immunization. Human antibodies from V-gene libraries displayed on phage." *J Mol Biol* 222(3): 581-97.
- C38 Marzo, I., C. Brenner, et al. (1998). "The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes." *Biomed Pharmacother* 52(6): 248-51.
- C39 Masood, R., J. Cai, et al. (1997). "Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma." *Proc Natl Acad Sci U S A* 94(3): 979-84.
- C40 Millauer, B., L. K. Shawver, et al. (1994). "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant." *Nature* 367(6463): 576-9.
- C41 Morrison, S. L. (1994). "Immunology. Success in specification [news; comment]." *Nature* 368(6474): 812-3.
- C42 Munson, P. J. and D. Rodbard (1980). "Ligand: a versatile computerized approach for characterization of ligand-binding systems." *Anal Biochem* 107(1): 220-39.
- C43 Neuberger, M. (1996). "Generating high-avidity human Mabs in mice [news; comment]." *Nat Biotechnol* 14(7): 826.
- C44 Poltorak, Z., T. Cohen, et al. (1997). "VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix." *J Biol Chem* 272(11): 7151-8.
- C45 Riechmann, L., M. Clark, et al. (1988). "Reshaping human antibodies for therapy." *Nature* 332(6162): 323-7.
- C46 Risau, W. (1995). "Differentiation of endothelium." *Faseb J* 9(10): 926-33.
- C47 Risau, W. and I. Flamme (1995). "Vasculogenesis." *Annu Rev Cell Dev Biol* 11: 73-91.
- C48 Rocchigiani, et al., 1998 "Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes." *Genomics* 47: 207-216. GenBank Accession Number: **O43915**
- C49 Romashkova, J. A. and S. S. Makarov (1999). "NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling [see comments]." *Nature* 401(6748): 86-90.
- C50 Shimizu, A., K. P. O'Brien, et al. (1999). "The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF- BB." *Cancer Res* 59(15): 3719-23.
- C51 Simon, M. P., F. Pedetour, et al. (1997). "Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma." *Nat Genet* 15(1): 95-8.
- C52 Speirs, V. and S. L. Atkin (1999). "Production of VEGF and expression of the VEGF receptors Flt-and KDR

APPLICANTS:
U.S.S.N.:

Shimke *et al.*
09/662,783

in primary cultures of epithelial and stromal cells derived from breast tumours." Br J Cancer 80(5-6): 898-903.

- C53 Tischer, E., R. Mitchell, et al. (1991). "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing." J Biol Chem 266(18): 11947-54.
- C54 Tsai, et al., 1998 "Fallotein, a novel growth factor like gene identified in human uterus." GenBank Accession Number: **Q9UL22**
- C55 Tsai, et al., 1999 "cDNA cloning of fallotein from mouse ovary." GenBank Accession Number: **Q9QY71**
- C56 Tsai, et al., 2000 "Identification of a novel platelet-derived growth factor-like gene, fallotein, in the human reproductive tract." Biochim. Biophys. Acta 1492(1) 196-202. GenBank Accession Number: **AAF00049**
- C57 Tsai, et al., 2000 "Identification of a novel platelet-derived growth factor-like gene, fallotein, in the human reproductive tract." Biochim. Biophys. Acta 1492(1) 196-202. GenBank Accession Number: **AF091434**
- C58 Verhoeven, M., C. Milstein, et al. (1988). "Reshaping human antibodies: grafting an antilysozyme activity." Science 239(4847): 1534-6.
- C59 Warren, R. S., H. Yuan, et al. (1995). "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis." J Clin Invest 95(4): 1789-97.
- C60 Wilcox, J. N., K. M. Smith, et al. (1988). "Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization." J Clin Invest 82(3): 1134-43.
- C61 Wilkinson, D. 2000. The Scientist. 14(8): 25-28.
- C62 Wozney, et al., 1988 "Novel regulators of bone formation: molecular clones and activities." Science 242(4885): 1528-1534. GenBank Accession Number: **PIR-ID:A58788**
- C63 Wozney, J. M., V. Rosen, et al. (1988). "Novel regulators of bone formation: molecular clones and activities." Science 242(4885): 1528-34.
- C64 Yamada, et al., "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D." Genomics: 42:483-488. GenBank Accession Number: **O35251**
- C65 Yoshikawa, H., K. Takaoka, et al. (1985). "Clinical significance of bone morphogenetic activity in osteosarcoma. A study of 20 cases." Cancer 56(7): 1682-7.
- C66 Yuan, F., Y. Chen, et al. (1996). "Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody." Proc Natl Acad Sci U S A 93(25): 14765-70.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


APPLICANTS:
U.S.S.N.:

Shimk *et al.*
09/662,783

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. CURA-77 (15966-577).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: December 19, 2000

TRADOCS:1414025.1(%B2H01!.DOC)